{"id":7241,"date":"2025-11-26T11:28:30","date_gmt":"2025-11-26T10:28:30","guid":{"rendered":"https:\/\/value-dossier.com\/?page_id=7241"},"modified":"2026-03-30T15:48:08","modified_gmt":"2026-03-30T13:48:08","slug":"pricing-and-analyses","status":"publish","type":"page","link":"https:\/\/value-dossier.com\/en\/pricing-and-analyses\/","title":{"rendered":"Pricing and Analyses"},"content":{"rendered":"\n
\n
\n\n
\n
\n

Pricing and Analyses<\/h1>\n <\/div>\n <\/div>\n\n <\/div>\n
\n
\n\n \"\"\n <\/div>\n <\/div>\n<\/section>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n\n
\n

Market and price analyses<\/h2>\n

Market and price analyses are a necessary prerequisite for classifying the market potential and the comparable medicinal products in an indication. With our tailored analyses, we can support you in positioning your product, assessing the market competition as well as a possible fixed amount group assignment, and preparing for AMNOG price negotiations.<\/p>\n

Conducting price analyses<\/h2>\n

Today, pricing is a multidimensional phenomenon that must consider the benefits and additional benefit compared to therapeutic alternatives, customer preferences, and reimbursement regulations. We conduct price analyses that consider your preferences, comparable therapy prices, and payer preferences.<\/p>\n <\/div>\n\n <\/div>\n<\/section>\n\n\n

\n
\n\n
\n
\n Budget impact analyses<\/summary>\n

The Drug Supply Strengthening Act (AMVSG) further strengthened the possibility of agreeing on price-volume models for new drugs in Section 130b of the German Social Code, Book V (SGB V). Accordingly, contract negotiations on reimbursement amounts increasingly involve not only prices but also quantity and volume components.<\/p>\n

Budget impact analyses play a central role in this process because they allow those responsible for costs to transparently assess the financial impact of a new drug. A robust budget impact model shows expected treatment costs and patient numbers and realistically reflects substitution and market developments. These models allow for the forecasting of expenditure trends over several years and the identification of economic risks at an early stage. We can provide you with a sound basis for presenting your position to the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in a comprehensible manner and for bringing realistic volume and price assumptions to the negotiations. Overall, budget impact analyses thus contribute significantly to creating planning security, objectifying arguments, and developing viable reimbursement and price\/volume models.<\/p>\n

We support you with well-founded budget impact analyses, enabling \u00a0you to develop an optimal pricing strategy and reimbursement positioning for your products. This includes the development of specific price\/volume models!<\/p>\n

 <\/p>\n<\/div>\n <\/details>\n

\n Reference price calculator<\/summary>\n

Reference pricing serves to limit prices within a reference price group and is considered an established control instrument for regulating drug prices (Section 35 SGB V, \u00a7 130a (3) SGB V). The reference price defines the maximum reimbursement amount covered by statutory health insurers within a specific reference price group. If the pharmacy retail price exceeds the reference price, patients must pay the difference as an additional co-payment on top of the statutory co-payment. Reference prices are regularly reviewed and adjusted by the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband. With our reference price calculator, we can simulate how future adjustments could affect the reimbursement amount of your products. Based on current market and comparative data, we analyze possible reference price reductions and show which price levels are realistic. This allows you to prepare for changes at an early stage and adjust your pricing strategy accordingly.<\/p>\n<\/div>\n <\/details>\n

\n Discount agreements<\/summary>\n

Discount agreements and tenders for discount agreements are a key instrument in Germany for reducing costs and gaining market access, particularly for generic medicinal products. To be successful in the generics market, participation in health insurance tenders is essential for many active ingredients. We provide comprehensive advice on tenders and analyze your chances of success in markets and with active ingredients that are of interest to you.<\/p>\n<\/div>\n <\/details>\n

\n Hospital reimbursement (NUBs)<\/summary>\n

For reimbursement of new examination and treatment methods (NUBs), a health economic analysis is performed to determine if they are covered by applicable DRG (diagnosis-related group) flat rates. Additional fees for NUBs are paid outside the hospital budget if they are not financed by the DRG system. Hospitals can submit NUB applications for separate reimbursement to the Institute for the Hospital Remuneration System (InEK) on October 1st of each year. Solely for gene therapies (ATMP) it is possible to submit applications during the year.<\/p>\n

 <\/p>\n

In the case of medical devices in risk classes 2b or 3, which are not covered by the DRG system, a benefit assessment in accordance with Section 137h of the German Social Code, Book V (SGB V) is carried out in addition to the health economic analysis.<\/p>\n

We offer all the services you need related to the reimbursement of drugs or medical devices in the inpatient sector. This includes advising on NUB applications and preparing for benefit assessments.<\/p>\n<\/div>\n <\/details>\n <\/div>\n\n <\/div>\n<\/section>\n\n\n

\n
\n\n
\n

Inflation adjustment<\/h2>\n

According to Section 130a (3a) sentence 2 of the SGB V, pharmaceutical companies can claim an inflation adjustment on the selling prices of drugs that are subject to the price moratorium. The base price is either the price as of August 1, 2009, or for products launched after August 1, 2010 the respective launch price. Inflation compensation can be applied for the first time since July 1, 2018, and adjusted on July 1st of each subsequent year. The amount of the adjustment is based on the consumer price index of the Federal Statistical Office and is cumulative (see Figure 1).<\/p>\n

We are happy to assist you in reviewing and calculating the permissible inflation adjustment for your products.<\/p>\n

 <\/p>\n